These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 22264043)

  • 1. Reverse transcriptase inhibitors as microbicides.
    Lewi P; Heeres J; Ariën K; Venkatraj M; Joossens J; Van der Veken P; Augustyns K; Vanham G
    Curr HIV Res; 2012 Jan; 10(1):27-35. PubMed ID: 22264043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel approaches to vaginal delivery and safety of microbicides: biopharmaceuticals, nanoparticles, and vaccines.
    Whaley KJ; Hanes J; Shattock R; Cone RA; Friend DR
    Antiviral Res; 2010 Dec; 88 Suppl 1():S55-66. PubMed ID: 21109069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical development of microbicides for the prevention of HIV infection.
    D'Cruz OJ; Uckun FM
    Curr Pharm Des; 2004; 10(3):315-36. PubMed ID: 14754390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific microbicides in the prevention of HIV infection.
    Kelly CG; Shattock RJ
    J Intern Med; 2011 Dec; 270(6):509-19. PubMed ID: 21917029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microbicides: topical prevention against HIV.
    Shattock RJ; Rosenberg Z
    Cold Spring Harb Perspect Med; 2012 Feb; 2(2):a007385. PubMed ID: 22355798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
    Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
    Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Historical development of vaginal microbicides to prevent sexual transmission of HIV in women: from past failures to future hopes.
    Notario-Pérez F; Ruiz-Caro R; Veiga-Ochoa MD
    Drug Des Devel Ther; 2017; 11():1767-1787. PubMed ID: 28670111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of UC781-tenofovir combination gel products for HIV-1 infection prevention in an ex vivo ectocervical model.
    Cost M; Dezzutti CS; Clark MR; Friend DR; Akil A; Rohan LC
    Antimicrob Agents Chemother; 2012 Jun; 56(6):3058-66. PubMed ID: 22430977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaginal microbicides and the prevention of HIV transmission.
    Cutler B; Justman J
    Lancet Infect Dis; 2008 Nov; 8(11):685-97. PubMed ID: 18992405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colorectal microbicide design: triple combinations of reverse transcriptase inhibitors are optimal against HIV-1 in tissue explants.
    Herrera C; Cranage M; McGowan I; Anton P; Shattock RJ
    AIDS; 2011 Oct; 25(16):1971-9. PubMed ID: 21811139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV microbicides: where are we now?
    Quiñones-Mateu ME; Vanham G
    Curr HIV Res; 2012 Jan; 10(1):1-2. PubMed ID: 22264039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmaceutical development of microbicide drug products.
    Friend DR
    Pharm Dev Technol; 2010 Dec; 15(6):562-81. PubMed ID: 20017601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dawn of non-nucleoside inhibitor-based anti-HIV microbicides.
    D'Cruz OJ; Uckun FM
    J Antimicrob Chemother; 2006 Mar; 57(3):411-23. PubMed ID: 16431862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design of tenofovir-UC781 combination microbicide vaginal gels.
    Kiser PF; Mahalingam A; Fabian J; Smith E; Damian FR; Peters JJ; Katz DF; Elgendy H; Clark MR; Friend DR
    J Pharm Sci; 2012 May; 101(5):1852-64. PubMed ID: 22359356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whither or wither microbicides?
    Grant RM; Hamer D; Hope T; Johnston R; Lange J; Lederman MM; Lieberman J; Miller CJ; Moore JP; Mosier DE; Richman DD; Schooley RT; Springer MS; Veazey RS; Wainberg MA
    Science; 2008 Jul; 321(5888):532-4. PubMed ID: 18653884
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Giacobbi NS; Sluis-Cremer N
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28507107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polyurethane intravaginal ring for controlled delivery of dapivirine, a nonnucleoside reverse transcriptase inhibitor of HIV-1.
    Gupta KM; Pearce SM; Poursaid AE; Aliyar HA; Tresco PA; Mitchnik MA; Kiser PF
    J Pharm Sci; 2008 Oct; 97(10):4228-39. PubMed ID: 18338805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MTN-033: a Phase 1 Study Comparing Applicator versus "as Lubricant" Delivery of Rectal Dapivirine Gel.
    Ho K; Dominguez-Islas C; Szydlo D; Edick S; Macagna N; Riddler SA; Brand RM; Jacobson CE; Kramzer L; Kunjara Na Ayudhya RP; Piper J; Marzinke MA; Bauermeister J; Nuttall J; Hillier SL; Hendrix CW
    Antimicrob Agents Chemother; 2022 Nov; 66(11):e0081622. PubMed ID: 36255254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formulation and delivery of microbicides.
    Agashe H; Hu M; Rohan L
    Curr HIV Res; 2012 Jan; 10(1):88-96. PubMed ID: 22264050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A silicone elastomer vaginal ring for HIV prevention containing two microbicides with different mechanisms of action.
    Fetherston SM; Boyd P; McCoy CF; McBride MC; Edwards KL; Ampofo S; Malcolm RK
    Eur J Pharm Sci; 2013 Feb; 48(3):406-15. PubMed ID: 23266465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.